CD20×CD3 双特异性抗体治疗淋巴瘤：2023 年美国临床肿瘤学会年会最新进展。
CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting.
机构信息
Institute of Biomedical Informatics, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, School of Basic Medical Sciences, Henan University, Kaifeng, 475004, Henan, China.
Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.
出版信息
J Hematol Oncol. 2023 Aug 3;16(1):90. doi: 10.1186/s13045-023-01488-4.
Abstract
Multiple bispecific antibodies (bsAbs) have been approved for cancer immunotherapy. Several CD20 × CD3 bsAbs have demonstrated significant anti-B-cell non-Hodgkin lymphoma (NHL) activity by engaging T cells to target CD20 NHL cells in clinical trials. Mosunetuzumab, epcoritamab and glofitamab have been approved recently for B-cell NHL therapy. In this study, we summarized several latest reports on CD20 × CD3 bsAbs for the therapy of B-cell NHL from the ASCO 2023 annual meeting (ASCO2023).
摘要
多种双特异性抗体（bsAbs）已被批准用于癌症免疫治疗。几项 CD20×CD3 bsAbs 在临床试验中通过招募 T 细胞来靶向 CD20 NHL 细胞，显示出显著的抗 B 细胞非霍奇金淋巴瘤（NHL）活性。Mosunetuzumab、epcoritamab 和 glofitamab 最近已被批准用于 B 细胞 NHL 治疗。在这项研究中，我们总结了 ASCO2023 年年会（ASCO2023）上关于 CD20×CD3 bsAbs 治疗 B 细胞 NHL 的几项最新报告。
相似文献
1
CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting.CD20×CD3 双特异性抗体治疗淋巴瘤：2023 年美国临床肿瘤学会年会最新进展。
J Hematol Oncol. 2023 Aug 3;16(1):90. doi: 10.1186/s13045-023-01488-4.
2
Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment.用于非霍奇金淋巴瘤治疗的双特异性抗体
Curr Treat Options Oncol. 2022 Feb;23(2):155-170. doi: 10.1007/s11864-021-00925-1. Epub 2022 Feb 19.
3
Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era.双特异性抗体在 CAR-T 时代复发/难治性弥漫性大 B 细胞淋巴瘤中的作用。
Front Immunol. 2022 Jul 19;13:909008. doi: 10.3389/fimmu.2022.909008. eCollection 2022.
4
Bispecific antibodies in indolent B-cell lymphomas.惰性B细胞淋巴瘤中的双特异性抗体
Front Immunol. 2024 Jan 11;14:1295599. doi: 10.3389/fimmu.2023.1295599. eCollection 2023.
5
Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.利妥昔单抗：用于非霍奇金淋巴瘤和慢性淋巴细胞白血病的综述
Drugs. 2003;63(8):803-43. doi: 10.2165/00003495-200363080-00005.
6
Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action.双特异性抗CD20/22抗体通过独特的作用机制抑制B细胞淋巴瘤增殖。
Blood. 2008 Feb 15;111(4):2211-9. doi: 10.1182/blood-2007-08-110072. Epub 2007 Nov 19.
7
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.戈利木单抗，一种新型、双价 CD20 靶向 T 细胞衔接双特异性抗体，在复发或难治性 B 细胞淋巴瘤中诱导持久完全缓解：一项 I 期试验。
J Clin Oncol. 2021 Jun 20;39(18):1959-1970. doi: 10.1200/JCO.20.03175. Epub 2021 Mar 19.
8
Update on bi-specific monoclonal antibodies for blood cancers.血液癌症的双特异性单克隆抗体的最新进展。
Curr Opin Oncol. 2023 Sep 1;35(5):441-445. doi: 10.1097/CCO.0000000000000966. Epub 2023 Jul 5.
9
Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 x anti-CD3 bispecific diabody.用抗CD20×抗CD3双特异性双抗体有效抑制人B细胞淋巴瘤异种移植瘤
Cancer Lett. 2002 Mar 8;177(1):29-39. doi: 10.1016/s0304-3835(01)00758-3.
10
Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial.异体造血干细胞移植后复发或难治性 B 细胞淋巴瘤的 FBTA05（Bi20）[一种三功能双特异性抗 CD3 x 抗 CD20 抗体]与供者淋巴细胞输注（DLI）联合免疫治疗：一项研究者发起的、开放标签、非随机、非对照、剂量递增的 I/II 期试验研究方案。
J Transl Med. 2013 Jul 2;11:160. doi: 10.1186/1479-5876-11-160.
引用本文的文献
1
QSP modeling of loncastuximab tesirine with T-cell-dependent bispecific antibodies guides dose-regimen strategy.loncastuximab tesirine与T细胞依赖性双特异性抗体的QSP建模指导剂量方案策略。
NPJ Syst Biol Appl. 2025 Jun 11;11(1):63. doi: 10.1038/s41540-025-00544-8.
2
Predictive factors and nomogram for the risk of cytokine release syndrome with anti-CD3 × CD20 bispecific antibodies for Chinese patients.中国患者使用抗CD3×CD20双特异性抗体发生细胞因子释放综合征风险的预测因素及列线图
Cancer Immunol Immunother. 2025 Jun 4;74(7):236. doi: 10.1007/s00262-025-04080-6.
3
LILRB1 enhances the progression of diffuse large B-cell lymphoma through the CREB-SORBS3 pathway.LILRB1通过CREB-SORBS3途径促进弥漫性大B细胞淋巴瘤的进展。
Cell Oncol (Dordr). 2025 May 7. doi: 10.1007/s13402-025-01060-x.
4
Immunotherapy in chronic lymphocytic leukemia: advances and challenges.慢性淋巴细胞白血病的免疫疗法：进展与挑战
Exp Hematol Oncol. 2025 Apr 10;14(1):53. doi: 10.1186/s40164-025-00644-5.
5
Characteristics of second primary malignancies following bispecific antibodies therapy.双特异性抗体治疗后第二原发性恶性肿瘤的特征。
J Immunother Cancer. 2025 Apr 5;13(4):e011200. doi: 10.1136/jitc-2024-011200.
6
Two Are Better than One: The Bi-Specific Antibody Mosunetuzumab Reveals an Improved Immune Response of Vγ9Vδ2 T Cells Targeting CD20 in Malignant B Cells in Comparison to the Mono-Specific Antibody Obinutuzumab.两人同心，其利断金：双特异性抗体莫苏奈妥珠单抗相较于单特异性抗体奥妥珠单抗，显示出靶向恶性B细胞中CD20的Vγ9Vδ2 T细胞免疫反应得到改善。
Int J Mol Sci. 2025 Jan 31;26(3):1262. doi: 10.3390/ijms26031262.
7
Construction and characterization of chimeric FcγR T cells for universal T cell therapy.用于通用型T细胞疗法的嵌合FcγR T细胞的构建与表征
Exp Hematol Oncol. 2025 Jan 15;14(1):6. doi: 10.1186/s40164-025-00595-x.
8
Next-Generation Therapeutic Antibodies for Cancer Treatment: Advancements, Applications, and Challenges.用于癌症治疗的下一代治疗性抗体：进展、应用与挑战
Mol Biotechnol. 2024 Sep 2. doi: 10.1007/s12033-024-01270-y.
9
A bioinspired supramolecular nanoprodrug for precision therapy of B-cell non-Hodgkin's lymphoma.一种仿生超分子纳米前药用于精准治疗 B 细胞非霍奇金淋巴瘤。
J Nanobiotechnology. 2024 Aug 10;22(1):475. doi: 10.1186/s12951-024-02745-5.
10
Bispecific and multispecific antibodies in oncology: opportunities and challenges.双特异性和多特异性抗体在肿瘤学中的应用：机遇与挑战。
Nat Rev Clin Oncol. 2024 Jul;21(7):539-560. doi: 10.1038/s41571-024-00905-y. Epub 2024 May 31.
本文引用的文献
1
Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting.莫舒替尼单抗与淋巴瘤：2022 年ASH 年会最新进展。
J Hematol Oncol. 2023 Jun 28;16(1):69. doi: 10.1186/s13045-023-01462-0.
2
Glofitamab therapy for diffuse large B cell lymphoma: latest updates from the 2022 ASH Annual Meeting.戈利木单抗治疗弥漫性大 B 细胞淋巴瘤：2022 年美国血液学会年会最新进展。
J Hematol Oncol. 2023 Mar 10;16(1):20. doi: 10.1186/s13045-023-01420-w.
3
Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment.用于非霍奇金淋巴瘤治疗的双特异性抗体
Curr Treat Options Oncol. 2022 Feb;23(2):155-170. doi: 10.1007/s11864-021-00925-1. Epub 2022 Feb 19.
4
CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies.CD20-TCB 联合奥滨尤妥珠单抗预处理用于血液系统恶性肿瘤的下一代治疗。
Clin Cancer Res. 2018 Oct 1;24(19):4785-4797. doi: 10.1158/1078-0432.CCR-18-0455. Epub 2018 May 1.
Zotero 插件